CEL-SCI CORP (CVM) Stock News

NYSEARCA:CVM - NYSE Arca - US1508376076 - Common Stock - Currency: USD

7.44 -0.79 (-9.6%)

After market: 7.4 -0.04 (-0.54%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CVM Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill - Mentions: RCON FTAI REPL IMAB ...

News Image

Which stocks are experiencing notable movement on Wednesday?

10 days ago - By: Chartmill - Mentions: RCON WING REPL SLRX ...

News Image

Let's have a look at the top gainers and losers in the middle of the day of today's session.

10 days ago - By: Benzinga - Mentions: ANIK PIII SLRX REPL ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: CEL-SCI Corporation

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

a month ago - By: Benzinga - Mentions: AAPL GILT RARE KALV ...

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

a month ago - By: CEL-SCI Corporation

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

a month ago - By: CEL-SCI Corporation

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

2 months ago - By: CEL-SCI Corporation

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Closing of Public Offering

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Pricing of Public Offering

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Proposed Public Offering

3 months ago - By: CEL-SCI Corporation

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

3 months ago - By: CEL-SCI Corporation

CEL-SCI Announces Combination of Common Stock

3 months ago - By: CEL-SCI Corporation

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

4 months ago - By: CEL-SCI Corporation

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

4 months ago - By: CEL-SCI Corporation

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

5 months ago - By: CEL-SCI Corporation

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients